Literature DB >> 25879008

Efficacy of different doses of sugammadex after continuous infusion of rocuronium.

Diego Soto Mesa1, Mounir Fayad Fayad1, Laura Pérez Arviza1, Verónica Del Valle Ruiz1, Fernando Cosío Carreño1, Luis Arguelles Tamargo1, Manuel Amorín Díaz1, Sergio Fernández-Pello Montes1.   

Abstract

AIM: To evaluate the effects of two different doses of sugammadex after maintenance anesthesia with sevofluorane and remifentanil and deep rocuronium-induced neuromuscular blockade (NMB).
METHODS: Patients between 20 and 65 years of age, with American Society of Anesthesiologists physical status classification I-II, undergoing gynecological surgery were included in a prospective, comparative and randomized study. NMB was induced with an injection of 0.6 mg/kg of rocuronium followed by continuous infusion of 0.3-0.6 mg/kg per hour to maintain a deep block. Anesthesia was maintained with sevofluorane and remifentanil. Finally, when surgery was finished, a bolus of 2 mg/kg (group A) or 4 mg/kg (group B) of sugammadex was applied when the NMB first response in the train-of-four was reached. The primary clinical endpoint was time to recovery to a train-of-four ratio of 0.9. Other variables recorded were the time until recovery of train-of-four ratio of 0.7, 0.8, hemodynamic variables (arterial blood pressure and heart rate at baseline, starting sugammadex, and minutes 2, 5 and 10) and adverse events were presented after one hour in the post-anesthesia care unit.
RESULTS: Thirty-two patients were included in the study: 16 patients in group A and 16 patients in group B. Only 14 patients each group were recorded because arterial pressure values were lost in two patients from each group in minute 10. The two groups were comparable. Median recovery time from starting of sugammadex administration to a train-of-four ratio of 0.9 in group A and B was 129 and 110 s, respectively. The estimated difference in recovery time between groups was 24 s (95%CI: 0 to 45 s, Hodges-Lehmann estimator), entirely within the predefined equivalence interval. Times to recovery to train-of-four ratios of 0.8 (group A: 101 s; group B: 82.5 s) and 0.7 (group A: 90 s; group B: 65 s) from start of sugammadex administration were not equivalent between groups. There was not a significant variation in the arterial pressure and heart rate values between the two groups and none of the patients showed any clinical evidence of residual or recurrent NMB.
CONCLUSION: A dose of 2 mg/kg of sugammadex after continuous rocuronium infusion is enough to reverse the NMB when first response in the Train-Of-Four is reached.

Entities:  

Keywords:  Monitoring neuromuscular function; Neuromuscular block antagonism; Neuromuscular block rocuronium; Rocuronium; Sugammadex

Year:  2015        PMID: 25879008      PMCID: PMC4391006          DOI: 10.12998/wjcc.v3.i4.360

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  29 in total

Review 1.  Is sugammadex economically viable for routine use.

Authors:  Thomas Fuchs-Buder; Claude Meistelman; Jan U Schreiber
Journal:  Curr Opin Anaesthesiol       Date:  2012-04       Impact factor: 2.706

2.  Recovery from neuromuscular blockade: a survey of practice.

Authors:  M Grayling; B P Sweeney
Journal:  Anaesthesia       Date:  2007-08       Impact factor: 6.955

3.  Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision.

Authors:  T Fuchs-Buder; C Claudius; L T Skovgaard; L I Eriksson; R K Mirakhur; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  2007-08       Impact factor: 2.105

4.  Neuromuscular effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia.

Authors:  D W Lowry; R K Mirakhur; G J McCarthy; M T Carroll; K C McCourt
Journal:  Anesth Analg       Date:  1998-10       Impact factor: 5.108

5.  Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients.

Authors:  T Suzuki; O Kitajima; K Ueda; Y Kondo; J Kato; S Ogawa
Journal:  Br J Anaesth       Date:  2011-04-29       Impact factor: 9.166

6.  Recovery from neuromuscular blockade after either bolus and prolonged infusions of cisatracurium or rocuronium using either isoflurane or propofol-based anesthetics.

Authors:  W S Jellish; M Brody; K Sawicki; S Slogoff
Journal:  Anesth Analg       Date:  2000-11       Impact factor: 5.108

7.  Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.

Authors:  Ozlem Sacan; Paul F White; Burcu Tufanogullari; Kevin Klein
Journal:  Anesth Analg       Date:  2007-03       Impact factor: 5.108

8.  A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.

Authors:  G Geldner; M Niskanen; P Laurila; V Mizikov; M Hübler; G Beck; H Rietbergen; E Nicolayenko
Journal:  Anaesthesia       Date:  2012-06-14       Impact factor: 6.955

9.  Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.

Authors:  Christopher Rex; Stefanie Wagner; Claudia Spies; Jens Scholz; Henk Rietbergen; Marten Heeringa; Hinnerk Wulf
Journal:  Anesthesiology       Date:  2009-07       Impact factor: 7.892

Review 10.  Sugammadex: clinical development and practical use.

Authors:  Thomas Fuchs-Buder; Claude Meistelman; Julien Raft
Journal:  Korean J Anesthesiol       Date:  2013-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.